| Sexualized drug use (chemsex') and high-risk sexual behaviours in HIV-positive men who have sex with men |
41 |
| Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0 |
21 |
| Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics |
18 |
| Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials |
11 |
| Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 |
9 |
| Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch? |
9 |
| Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort |
8 |
| Towards person-centred care for people living with HIV: what core outcomes matter, and how might we assess them? A cross-national multi-centre qualitative study with key stakeholders |
8 |
| Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion |
8 |
| Rates of sustained virological response 12weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? |
8 |
| Towards elimination of HIV transmission, AIDS and HIV-related deaths in the UK |
7 |
| Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen |
7 |
| Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD) |
6 |
| Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps |
6 |
| De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings |
6 |
| Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999-2013) |
6 |
| Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort |
6 |
| HIV-infected patients' beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy |
6 |
| British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 |
6 |
| Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication |
5 |
| BCN Checkpoint: same-day confirmation of reactive HIV rapid test with Point Of Care HIV-RNA accelerates linkage to care and reduces anxiety |
5 |
| InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes |
5 |
| Findings from home-based HIV testing and facilitated linkage after scale-up of test and treat in rural South Africa: young people still missing |
5 |
| Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide |
5 |
| Depression and all-cause mortality risk in HIV-infected and HIV-uninfected US veterans: a cohort study |
5 |
| Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study |
5 |
| The world-wide incidence of Kaposi's sarcoma in the HIV/AIDS era |
5 |
| British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019 |
5 |
| Acute kidney injury in HIV-infected patients: a critical review |
4 |
| Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naive for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014 |
4 |
| Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research Network |
4 |
| Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life |
4 |
| Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence |
4 |
| HIV in practice: current approaches and challenges in the diagnosis, treatment and management of HIV infection in Australia |
4 |
| National audit of perinatal HIV infections in the UK, 2006-2013: what lessons can be learnt? |
4 |
| Missed opportunities to prevent mother-to-child transmission of HIV in Italy |
4 |
| Level of agreement between frequently used cardiovascular risk calculators in people living with HIV |
4 |
| The challenge of discriminating between HIV- HIV-2 and HIV-1/2 dual infections |
4 |
| Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men |
4 |
| A structural equation model to predict pre-exposure prophylaxis acceptability in men who have sex with men in Leicester, UK |
4 |
| Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review |
4 |
| Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls |
4 |
| HIV incidence is rapidly increasing with age among young men who have sex with men in China: a multicentre cross-sectional survey |
4 |
| Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study |
4 |
| Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders |
4 |
| To prescribe, or not to prescribe: decision making in HIV-1 post-exposure prophylaxis |
3 |
| Diabetes, mortality and glucose monitoring rates in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) study |
3 |
| Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals |
3 |
| Risk factors for loss to follow-up, transfer or death among people living with HIV on their first antiretroviral therapy regimen in Mali |
3 |
| Persistence rate of cervical human papillomavirus infections and abnormal cytology in Rwanda |
3 |
